Biotech · Public company · Morristown, NJ, US
Altimmune, Inc.
Ticker ALT · SEC CIK 0001326190
Track this companyFree. Adds Altimmune, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials172 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline16
- PemvidutidePhase 3 · Metabolic Dysfunction-Associated Steatohepatitis (MASH)ClinicalTrials.gov · fetched Nov 12, 2026
- ALT-801Phase 2 · Obesity/OverweightClinicalTrials.gov · fetched Nov 12, 2026
- HepTcellPhase 2 · Hepatitis B, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- NasoVAXPhase 2 · Coronavirus InfectionClinicalTrials.gov · fetched Nov 12, 2026
- NasoVAXPhase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- PemvidutidePhase 2 · Non-Alcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- PemvidutidePhase 2 · Alcohol-associated Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PemvidutidePhase 2 · Alcohol Use Disorder (AUD)ClinicalTrials.gov · fetched Nov 12, 2026
- AdCOVIDPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- ALT-801Phase 1 · Type 2 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- ALT-801Phase 1 · Non-Alcoholic Fatty Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- BioThraxPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- NasoShieldPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- Pandemic Influenza VaccinePhase 1 · Influenza A Subtype H5N1 InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Licensed seasonal influenza vaccineInfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Subjects were administered NasoVAX high doseInfluenzaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials17
- Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHPHASE3 · RECRUITING · started Jul 30, 2026ClinicalTrials.gov NCT07795164 · fetched Nov 12, 2026
- RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 16, 2025ClinicalTrials.gov NCT07009860 · fetched Nov 12, 2026
- RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightPHASE2 · COMPLETED · started May 15, 2025ClinicalTrials.gov NCT06987513 · fetched Nov 12, 2026
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)PHASE2 · COMPLETED · started Jul 27, 2023ClinicalTrials.gov NCT05989711 · fetched Nov 12, 2026
- Efficacy and Safety of ALT-801 in the Treatment of ObesityPHASE2 · COMPLETED · started Mar 31, 2022ClinicalTrials.gov NCT05295875 · fetched Nov 12, 2026
- Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)PHASE1 · COMPLETED · started Mar 9, 2022ClinicalTrials.gov NCT05292911 · fetched Nov 12, 2026
- ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)PHASE1 · COMPLETED · started Feb 1, 2022ClinicalTrials.gov NCT05134662 · fetched Nov 12, 2026
- ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)PHASE1 · COMPLETED · started Sep 30, 2021ClinicalTrials.gov NCT05006885 · fetched Nov 12, 2026
- Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)PHASE1 · COMPLETED · started Feb 25, 2021ClinicalTrials.gov NCT04679909 · fetched Nov 12, 2026
- HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)PHASE2 · TERMINATED · started Dec 26, 2020ClinicalTrials.gov NCT04684914 · fetched Nov 12, 2026
- NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)PHASE2 · TERMINATED · started Oct 10, 2020ClinicalTrials.gov NCT04442230 · fetched Nov 12, 2026
- NasoShield in Healthy Adults to Study Safety and ImmunogenicityPHASE1 · COMPLETED · started Jun 15, 2020ClinicalTrials.gov NCT04415749 · fetched Nov 12, 2026
- Study of the Safety and Immunogenicity of NasoVAX ExtensionCOMPLETED · started Jan 21, 2019ClinicalTrials.gov NCT03760549 · fetched Nov 12, 2026
- NasoShield Study of Safety and ImmunogenicityPHASE1 · COMPLETED · started Jan 18, 2018ClinicalTrials.gov NCT03352466 · fetched Nov 12, 2026
- Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAXPHASE2 · COMPLETED · started Sep 18, 2017ClinicalTrials.gov NCT03232567 · fetched Nov 12, 2026
- Immune Response Following Seasonal Influenza VaccinationPHASE4 · COMPLETED · started May 8, 2017ClinicalTrials.gov NCT03163342 · fetched Nov 12, 2026
- Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.PHASE1 · COMPLETED · started Oct 1, 2008ClinicalTrials.gov NCT00755703 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 28, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 16, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Apr 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 16, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 6, 2026 · fetched Nov 12, 2026